Travere Therapeutics, Inc.
TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients witā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$44.55
Price+3.99%
$1.71
1Y
Price
Market Cap
$4.143b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-9.2%
EBITDA Margin-29.2%
Net Profit Margin-49.2%
Free Cash Flow Margin-9.2%
EBITDA Margin-29.2%
Net Profit Margin-49.2%
Free Cash Flow MarginRevenue
$536.196m
+9.3%
1y CAGR+60.1%
3y CAGR+53.2%
5y CAGREarnings
-$21.422m
+16.1%
1y CAGR-26.8%
3y CAGR-5.1%
5y CAGREPS
-$0.53
+5.4%
1y CAGR-26.8%
3y CAGR-3.7%
5y CAGRBook Value
$98.728m
$555.188m
Assets$456.460m
Liabilities$327.662m
DebtDebt to Assets
59.0%
9.1x
Debt to EBITDAFree Cash Flow
$17.434m
-53.9%
1y CAGR+17.3%
3y CAGR+0.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company